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Opinion statement
Two recently reported phase III randomised control trials (RCTs) have resulted
in the registration of two new systemic therapies for advanced soft tissue
sarcoma. Both of these trials’ designs were informed by phase II data that
guided the selection of sensitive STS diagnoses, enabling the demonstration of
benefit in certain subtypes. A number of other phase III trials reported in the
last 18 months have seemingly fit into a recurrent pattern of failure—promising
efficacy signals in earlier phase studies being lost in the survival follow-up of
large, highly heterogeneous cohorts. Greater effort is needed to identify histo-
logical and molecularly defined subgroups associated with differential treatment
response in order to avoid the tremendous disappointment and loss of resources
associated with a failed phase III trial. Additionally, improvements in available
treatment of advanced STS have underpinned a prolongation in overall survival
(OS). Consequently, surrogate efficacy endpoints are of increasing importance
to STS drug trials. Whilst progression-free survival (PFS) should arguably replace
overall survival as the primary endpoint of choice in first-line studies, more
work is required to provide definitive validation of surrogacy, as well as
developing more sophisticated techniques of assessing radiological response
and expanding the inclusion of quality-of-life-related endpoints.
Introduction
Cytotoxic chemotherapy is themainstay of treatment for
advanced STS (Table 1). First introduced in the 1970s,
doxorubicin was one of the first anticancer agents to
consistently produce meaningful rates of response in
advanced STS, and remains a standard of first-line ther-
apy [2]. Over the ensuing years, many other cytotoxic
agents have been trialled in this setting, with only a
handful demonstrating meaningful efficacy in unselect-
ed STS populations [5–10]. The combination of doxo-
rubicin with a second active agent has been investigated
on a number of occasions—whilst these more intensive
schedules have often produced favourable rates of re-
sponse at the expense of higher levels of toxicity, no trial
has shown evidence of prolonged survival with combi-
nation therapy [2, 3••]. The differential efficacy of some
drugs in certain STS subtypes has been highlighted, such
as the case of paclitaxel in angiosarcoma [22, 23]. Mean-
while, beyond the targeting of mutated KIT and
PDGFRA in gastrointestinal stromal tumours, emergent
understanding of underlying molecular pathology has
informed certain therapeutic strategies in rarer STS sub-
types [20, 21, 24, 25]. Additionally, the multi-targeted
tyrosine kinase inhibitor pazopanib was approved in
2012 and remains the only molecularly targeted agent
approved across many different STS subtypes [11••].
The rarity and heterogeneity of STS pose a recurrent
challenge to the design and conduct of adequately
powered phase III drug trials. Although two recently
reported studies have successfully led to new drug ap-
provals, the majority of phase III trials have failed to
Table 1. Current standard systemic therapies for advanced STS
Drug Type Indication NIH NCI
Level of
evidence [1]
References
Doxorubicin Anthracycline First line 3iiiDiv [2]
Doxorubicin +
ifosfamide
Anthracycline + alkylating agent First line (esp. chemo-sensitive
subtypes/ bulky disease)
1iiDiii [3]
Doxorubicin +
olarutumab
Anthracycline + anti-PDGFRα
monoclonal antibody
First line 1iiA [4•]
Ifosfamide Alkylating agent Second line 1iiDiv [5–7]
Gemcitabine +
dacarbazine
Nucleoside analogue + alkylating
agent
Second line 1iiA [8]
Gemcitabine +
docetaxel
Nucleoside analogue + taxane Second line (potentially first line in
some subtypes
1iiDiii [9, 10]
Pazopanib Multi-targeted kinase inhibitor
(activity against VEGFRs,
PDGFRα, FGFR1, KIT)
Second line and beyond in
non-adipocytic STS
1iDiii [11••]
Eribulin Microtubule inhibitor Second line (after anthracycline) 1iiA [12••]
Trabectedin DNA minor groove binder Second to third line (after
anthracycline and ifosfamide)
1iiDiii [13••, 14]
Dacarbazine Alkylating agent Third line 3iiiDiv [15, 16]
Liposomal
doxorubicin
Anthracycline Kaposi and angiosarcoma
Substitute for doxorubicin in most STS
3iiiDiv [17–19]
Sirolimus mTOR inhibitor Malignant PEComa 3iiiDiv [20, 21]
Paclitaxel Taxane Kaposi and angiosarcoma 3iiiDiv [17, 22, 23]
Crizotinib Multi-targeted kinase inhibitor
(activity against ALK, ROS1,
MET)
Inflammatory myofibroblastic tumour 3iiiDiv [24]
Imatinib Multi-targeted kinase inhibitor
(activity against KIT, PDGFRA,
BCR-ABL)
Dermatofibrosarcoma protuberans 3iiDiv [25]
 19 Page 2 of 16 Curr. Treat. Options in Oncol.  (2017) 18:19 
result in new treatment registrations. In this review,
we aim to provide an overview of recently reported
phase III drug trials in advanced STS (summarised
in Table 2) and examine the factors in trial design
that may have contributed to their respective success
or failure.
Recent successes—phase III studies resulting in new drug
registration
Eribulin
Eribulin mesilate is a synthetic analogue of a compound derived from the
marine spongeHalichondria okadai. Eribulin disrupts microtubule propagation,
conferring anticancer effects that include suppression of cancer cell migration
and invasion, induction of vascular remodelling and reversal of epithelial-
mesenchymal transition. Eribulin is approved for use in pre-treated metastatic
breast cancer and has demonstrated single agent activity in advanced non-small
cell lung cancer [31, 32].
A phase II trial conducted by the European Organisation for Research and
Treatment of Cancer (EORTC) identified leiomyosarcoma (LMS) and
liposarcoma (LPS), the so-called L-sarcomas, as STS subtypes of apparent
sensitivity to eribulin [33]. In this non-controlled study, four independent
subtype-defined arms were treated with eribulin with a primary outcome of
12-week progression-free survival rate (12w PFS). After treatment of 115 pa-
tients, 12w PFS in the LMS and LPS arms were 31.6 and 46.9%, respectively,
whilst the synovial sarcoma and heterogeneous ‘other STS’ strata failed to meet
the pre-specified 930% 12w PFS efficacy cutoff (12w PFS 21.1 and 19.2%,
respectively).
A subsequent open-label phase III RCT of eribulin limited recruitment to the
apparently sensitive L-sarcomas subtypes [12••]. Patients with pre-treated ad-
vanced disease were randomised to receive either eribulin or dacarbazine
therapy until disease progression, unacceptable toxicity or withdrawal of pa-
tient consent. After randomisation of 452 patients and a median follow-up of
31 months, a statistically significant improvement in overall survival in the
eribulin arm was seen (HR0.77, 95% CI 0.62–0.95, p = 0.0169). No difference
in response, disease control and quality of life endpoints were seen between the
study arms, whilst median PFS of 2.6 months was seen in both arms. Tolera-
bility was broadly equivalent between both arms, although an excess of grade
1–2 peripheral neuropathy (19 vs 4%) and grade 3–4 neutropaenia (35 vs
16%) was seen in the eribulin arm. In analysis of pre-specified subgroups, the
LPS group received a pronounced OS benefit with eribulin (median OS 15.6 vs
8.4 m, HR 0.511; 95% CI 0.35–0.75), whilst patients with LMS had similar
outcomes regardless of treatment allocation (median OS 12.8 vs 12.3 m, HR
0.93; 95% CI 0.71–1.20). A 1.2-m increase in median PFS with eribulin in the
LPS group reached statistical significance (HR 0.52, 95% CI 0.35–0.78) but was
notably dwarfed by the 7.2-mOS gain in this subgroup. The trial technically did
not have sufficient statistical power to test for interaction between eribulin effect
and histological subtype, but regulatory bodies and others have interpreted
these results as demonstrating that eribulin has a survival benefit over
dacarbazine in LPS only.
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Trabectedin
Trabectedin is a marine-derivative antineoplastic agent with anticancer effects
believed to primarily relate to binding to the minor groove of DNA, resulting in
inhibition of transcription, DNA repair and replication [34]. Additional effects
of trabectedin may also include modulation of tumour microenvironment
factors including microvasculature and tumour-infiltrating macrophages [35].
Trabectedin has been shown to have particular effect in translocation-associated
sarcomas such as myxoid LPS, where preclinical research has shown that
trabectedin can reverse the transcriptional reprogramming orchestrated by the
pathognomonic FUS-CHOP fusion gene [36].
Following encouraging results from three non-comparative studies, the first
randomised evidence of trabectedin efficacy in advanced STS was from a phase
II study where patients with pre-treated L-sarcomas were randomly allocated to
one of two different trabectedin schedules (1.5 mg/m2 over 24 h q3w vs.
0.58 mg/m2 over 2 h weekly for three consecutive weeks in a 4-week cycle)
[37]. Although lacking a non-trabectedin comparator arm, the superior time-to-
progression and PFS of the 24 h schedule compared to the weekly dosing arm
and to EORTC-defined efficacy benchmarks led to European approval in 2007
for use of trabectedin in STS following anthracycline and ifosfamide. The
efficacy of trabectedin in translocation-associated sarcomas was established by
a Japanese randomised phase II trial, where trabectedin (24-h infusion) con-
ferred a large PFS benefit compared to best supportive care alone (median PFS
5.6 vs 0.9 m; HR 0.07; 95% CI 0.03–0.16; p G 0.0001) [38••]. The Japanese trial
followed an international phase III study comparing trabectedin to doxorubicin
in a first-line setting. This earlier study closed early after interim analysis led to
an impractical inflation of target sample size as a response to high rates of
patient drop-out and lack of any large early efficacy signal [39].
Two recently reported phase III trials have provided definitive evidence of
the efficacy of 24 h infusional trabectedin compared to non-trabectedin control
in less selected STS populations. The earlier and larger of these recruited 518
patients with pre-treated L-sarcomas (approximately 75% LMS, 25% LPS) and
randomised 2:1 to either trabectedin or dacarbazine [13••]. A statistically
significant improvement in median PFS was seen with trabectedin (4.2 vs
1.5months), whilst the significant improvement in clinical benefit rate (defined
as maintained response or stable disease to at least 18 weeks—34 vs 19%;
p G 0.001) but not objective response rate (9.9 vs 6.9%) highlighted the largely
tumour static effect of trabectedin in a pre-treated trial cohort where 950%
patients had experienced progressive disease as best response to their previous
line of therapy. Interim analysis of the trial’s primary OS endpoint after 50% of
target OS events had occurred showed no difference between treatment arms.
Whilst follow-up continued to allow for currently unreported final OS analysis,
the authors noted that the better-than-expected median OS of 12.9 months in
the dacarbazine arm suggested that post-trial treatments may mask any evi-
dence of OS benefit of trabectedin. This evidence of trabectedin effect led to US
Food and Drug Administration (FDA) approval being granted for pre-treated L-
sarcoma in November 2015.
The T-Sar trial, recently reported at the annual meeting of the European
Society of Medical Oncology, was conducted by the French Sarcoma Group
[14]. In this phase III trial, 107 patients who had received between 1 and 3 prior
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lines of systemic therapy for advanced sarcomas of mixed subtype were
randomised to receive either trabectedin or best supportive care with optional
post-progression crossover. A doubling of median PFS was seen in the
trabectedin arm at interim efficacy reporting (3.0 vs 1.4 m, HR 0.40; 95% CI
0.26–0.63, p G 0.0001). A significant PFS advantage with trabectedin was seen
in both L-sarcoma and non-L-sarcoma subgroups—the numerically greater
effect size in the L-sarcoma group (HR 0.33 vs 0.49) was not powered for
statistical comparison to the non-L-sarcoma group. Regardless, this trial pro-
vides the first randomised comparative data to support the efficacy of
trabectedin in pre-treated patients across multiple STS subtypes.
Recent phase III studies that failed to improve on standard of
care
Palifosfamide
Efforts to improve the efficacy of alkylating drugs in STS chemotherapy regi-
mens whilst reducing ifosfamide-specific toxicities led to the development of
palifosfamide, the active DNA-alkylating metabolite of ifosfamide. The use of
palifosfamide avoids the production of the metabolic by-products that are
thought to be responsible for ifosfamide-related encephalopathy, haemorrhagic
cystitis and renal toxicity. Additionally, the more predictable pharmacokinetics
of palifosfamide bolstered hopes of improved efficacy compared to ifosfamide.
Following randomised phase II data indicating the superiority of combina-
tion palifosfamide-doxorubicin compared to doxorubicin alone, PICASSO III
was a double-blind, placebo-controlled phase III RCT aimed at demonstrating
superior survival from using upfront anthracycline-alkylator combination [26•,
40]. Patients with untreated advanced STS of a broad range of subtypes were
randomised 1:1 to treatment with doxorubicin combined with either
palifosfamide or placebo to a maximum of six cycles. This design mirrored that
of the earlier EORTC 62012 open-label trial, where in a mixed STS population
with confirmed progressing disease, the combination of ifosfamide with doxo-
rubicin failed to demonstrate a significant advantage in overall survival despite
improvements secondary PFS and response outcomes [3••]. After treatment of
447 randomised patients in PICASSO III, no significant difference in PFS or OS
were seen between palifosfamide and placebo-containing arms, despite im-
proved rates of objective response and disease control with palifosfamide. In
pre-planned subgroup analysis, there was no survival benefit with
palifosfamide in any age or subtype-defined patient groups. In the overall
cohort, higher rates of haematological toxicity and febrile neutropaenia were
seen in the palifosfamide-containing arm. There were incidences of encepha-
lopathy and haemorrhagic cystitis seen in the palifosfamide arm, but these were
much lower than historically reported in ifosfamide-based studies. Due to the
lack of difference in median PFS and OS between the doxorubicin alone and
doxorubicin/palifosfamide arms, further development of this drug has been
terminated.
Evofosfamide
Evofosfamide (TH-302) is a prodrug that is converted under hypoxic conditions
to an active DNA-alkylating metabolite. It has been predicted that preferential
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metabolic activation of evofosfamide in the relative hypoxia of the tumour bed
would reduce systemic levels of toxic metabolites whilst enhancing efficacy
relative to ifosfamide [41]. Following dose-finding phase I studies of
evofosfamide in combination with doxorubicin, a single-arm phase II trial of
the combination in first-line advanced STS reported encouraging rates of ob-
jective response, progression-free and overall survival [42, 43].
In the open-label SARC021 phase III trial, a cohort of 640 patients with
untreated advanced STS that was unselected by subtype or any marker of
tumour hypoxia were randomised to receive either doxorubicin alone or in
combination with evofosfamide, with those not progressing on combination
able to continue maintenance evofosfamide after completion of 6 cycles of
doxorubicin-containing therapy [30•]. Similar to the PICASSO III trial, objec-
tive evidence of recent disease progression was not required prior to patient
enrolment in SARC021–EORTC 62012 mandated progression within 6 weeks
of commencing trial therapy. In SARC021, there was no significant difference
between combination and single agent arms in progression-free survival (me-
dian PFS 6.3 vs 6.0 months, HR 0.85, 95% CI 0.70–1.03; p = 0.099) or overall
survival (median OS 18.4 vs 19 months, HR 1.06; 95% CI 0.88–1.29). Despite
protocol-mandated use of primary GCSF prophylaxis in the combination arm,
higher rates of febrile neutropaenia were seen with doxorubicin-evofosfamide
compared to doxorubicin alone (18.2 vs 11.0%), whilst greater levels of grade
3–4 fatigue, GI disturbance and nutritional disorder were also seen with com-
bination treatment. These disappointing phase III results have led to the dis-
continuation of the development of evofosfamide in advanced STS.
Gemcitabine and docetaxel
Whilst both gemcitabine, a nucleoside analogue, and docetaxel, a taxane,
possess modest single agent activity in advanced STS, combination schedules
of the two drugs produced response rates ranging between 14 and 53% in non-
comparative phase II trials [44, 45]. The activity of gemcitabine-docetaxel
regimens (GemTax) that employ optimised fixed-dose-rate administration of
gemcitabine have been compared to gemcitabine alone in two separate
randomised phase II studies in advanced STS. The earlier SARC002 trial
employed a Bayesian adaptive model to randomise 122 patients with mixed
advanced STS (60%GemTax, 40% gemcitabine alone) and found superiority of
GemTax in terms of objective responses, clinical benefit rate, PFS and OS [9]. In
contrast, the French study reported no improvement in outcomes with a similar
GemTax schedule in LMS patients randomised through a more conventional
statistical design [10]. Regardless, based on the cumulative evidence of activity,
combination gemcitabine and docetaxel is established in the armamentarium
in the majority of STS subtypes, particularly leiomyosarcoma and undifferenti-
ated pleomorphic sarcoma.
In the GEDDIS trial, an open-label UK phase III trial reported at ASCO2015,
the efficacy, tolerability and safety of GemTax was compared to that of standard
doxorubicin in the first-line treatment of intermediate-to-high grade advanced
STS of unselected subtype [28]. After treatment of randomised 257 patients,
there was no significant difference in the primary endpoint of 24-week progres-
sion-free survival rate between the doxorubicin and GemTax arms (46.1 vs
46.0%, respectively). The hazard ratio for PFS numerically favoured
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doxorubicin (HR 1.28, 95% CI 0.98–1.67, p = 0.07) whilst no significant
difference in objective response rate andmedian overall survival was seen. Dose
delays and toxicity-related discontinuation were higher with GemTax. No dif-
ferences in efficacy outcomewere reported between subtype-defined subgroups,
where 27% of patients had uterine LMS and 56% were categorised as ‘other
STS’. This result appears to confirm that for an unselected STS population, single
agent doxorubicin should be the preferred first-line option, given greater toler-
ability and potentially favourable efficacy.
Gemcitabine and docetaxel with bevacizumab
There has been little reported evidence to support a role for the anti-vascular
endothelial growth factor (VEGF) monoclonal antibody bevacizumab in the
treatment of STS. The combination of bevacizumab with doxorubicin in a phase
II study in unselected STS subtypes failed to surpass efficacy levels expected for
doxorubicin alone, with a safety signal that suggested an increase in cardiac
toxicity [46]. Optimism for bevacizumab in STS of blood vessel originwas quelled
by a randomised phase II trial that failed to demonstrate incremental efficacy from
the addition of bevacizumab to standard paclitaxel chemotherapy [47].
In a recently reported placebo-controlled phase III RCT conducted in
the USA, the addition of bevacizumab to GemTax backbone was compared
to a control arm of GemTax-placebo in a subtype-selective protocol that
specifically recruited advanced uterine LMS [27]. Following randomisation
of 107 patients with chemo-naive advanced disease, numerically but non-
significantly worse PFS and OS were seen in the bevacizumab arm (medi-
an PFS 4.2 vs 6.2 m, HR1.12, p = 0.58; median OS 26.9 vs 23.3, HR 1.07,
p = 0.81) with no difference in ORR, CBR or median duration of response
seen between trial arms. These results add further questions as to any
potential role of bevacizumab in this and other STS subtypes, although
the trial highlighted the feasibility of performing and completing subtype-
selective phase III drug trials within 4 years of first patient recruitment.
Ombrabulin with cisplatin
Ombrabulin is a combrestatin-type vascular disrupting agent with demonstrat-
ed single agent anti-tumour activity through irreversible devascularisation.
Therapeutic synergy of ombrabulin with cisplatin has been shown in preclinical
and phase I studies [48, 49]. In an industry-sponsored double-blinded phase III
trial in pre-treated advanced STS ofmixed subtype, patients were randomised to
receive either ombrabulin (25 mg/m2 q3w) or placebo in addition to a chemo-
therapy backbone of cisplatin (75 mg/m2 q3w) [29]. After randomisation of
355 patients, a statistically significant improvement in PFS was seen in the
ombrabulin-containing arm, but the absolute gain in median PFS of less than
1 week was deemed clinically insignificant (median PFS 1.54 vs 1.41 m, HR
0.76, 95% CI 0.59–0.98, p = 0.0302). No significant difference in overall
survival was seen between study arms (median OS 11.4 vs 9.3 m, HR 0.85,
95% CI 0.67–1.09, p = 0.197). Response and clinical benefit rates were numer-
ically higher in the ombrabulin arm (4 vs 1% and 47 vs 36%, respectively), as
were rates of grade 3–4 neutropaenia (31 vs 19%). The small observed degree of
incremental efficacy against a non-standard comparator arm has resulted in
cessation of clinical development of ombrabulin in STS.
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Where did things go right? Where did things go wrong?
Choice of endpoint
Overall survival, defined as time from randomisation to point of death from
any cause, is the traditional gold standard endpoint in advanced STS phase
III trials. Objective and precise, OS provides an unambiguously meaningful
measure of treatment benefit. However, the large sample sizes and
prolonged patient follow-up required for adequately powered OS analysis
are a particular challenge in rare cancers. Furthermore, subsequent lines of
post-trial therapy may confound the effect of any investigative agent on OS.
Historically, first-line advanced STS drug trials were relatively shielded from
these effects, given expected median overall survival of less than 1 year in
control arms and few available further lines of therapy. However, recent
first-line trials have reported median overall survival of 14.7–19.0 months
in doxorubicin-only arms [3••, 4•, 26•, 30•]. This is a likely reflection of
increasing trends for aggressive localised management of oligometastatic
disease, a greater number of effective systemic therapies and improved
access to specialist supportive and palliative care services. Longer follow-
up is now required to measure OS in advanced STS, during which there is
greater scope for confounding by post-trial treatment. It will be increasingly
challenging for new treatments of advanced STS to demonstrate OS benefit,
particularly where treatment effect is diluted by biological heterogeneity.
As clinical decisions to change treatment are typically based on evidence of
disease progression, the use of endpoints based around progression events are
of clear clinical meaning and are increasingly used in oncology trials as an OS
surrogate. PFS, defined as the time from randomisation to disease progression
or death, is not influenced by post-trial treatments, providing an earlier and
increasingly clearer readout of treatment effect compared to OS. Whilst PFS is
well validated in many tumour types and widely accepted by regulatory bodies
as a legitimate efficacy measure, there remain limitations to its use as an
endpoint in advanced STS. Little work has been performed to establish valid
surrogacy of PFS for OS in STS. Assessment of disease progression is subjective
and is vulnerable to bias in unblinded trials, potentially contributing to poor
correlation between PFS and OS gains. Whilst PFS captures the benefit of
cytostatic agents associated with low objective response rates, PFS can underes-
timate the benefit of treatments associated with unusual patterns of response,
such as the cystic responses seen with some anti-angiogenic agents. Meanwhile,
several recent STS drug trials have demonstrated largeOS benefits in the absence
of significant PFS improvement, calling into question the specificity of PFS as a
surrogate for OS.
Patient quality of life (QoL) is an integral efficacy endpoint that can reflect
changes in disease-related symptomburden, drug tolerability and psycho-social
function of integral clinical meaning. Drug regulators are increasingly require
supporting QoL data when considering new drugs for marketing authorisation,
a trend reflected by the inclusion of QoL-related secondary endpoints in recent
STS phase III trials. The expanded inclusion of QoL assessment to all phase III
drug trials in STS should be matched by the continued development of valid
and meaningful QoL measures specific to STS patients.
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Cohort selection
A majority of phase III drug trials performed in advanced STS over the past
30 years have recruited cohorts consisting of many different disease subtypes. A
recent systematic review found that of 52 RCTs performed in STS between 1974
and 2014, only 7 of 52 (13%) included trials recruited from a single specified
subtype [50]. Whilst permitting recruitment across a mix of STS subtypes in-
creases the practicality of assembling sufficiently powered phase III cohorts, such
‘all-comer’ eligibility criteria introduces marked biological heterogeneity that
may dictate widely varying sensitivity to an investigative treatment. It is therefore
perhaps unsurprising that, in many cases, investigative treatments that have
shown promising surrogate efficacy signals in small phase II studies fail to confer
an aggregate survival advantage in larger, more heterogeneous phase III cohorts.
In the past 3 years, three large phase III trials have failed to demonstrate a
survival advantage from combining an active alkylator with standard doxorubi-
cin in the first-line treatment of similar ‘all-comers’ advanced STS cohorts [3••,
26•, 30•]. Across EORTC 62012, PICASSO III and SARC021, a strikingly consis-
tent absolute increase of around 10% in objective response rates was seen with
combination therapy, suggesting the presence of a disease subgroup with differ-
ential sensitivity. However, such a subgroup was not identifiable through anal-
ysis of histological or clinical factors in any of the studies, indicating some
unidentified facet of disease that transcends established stratification factors.
Meanwhile, this efficacy signal is diluted during follow-up of the entire cohort,
resulting in the failure to translate into evidence of prolonged survival.
In contrast to these studies, the two phase III trials that have recently led to
successful registration of eribulin and trabectedin both recruited from selected
STS subtypes that had demonstrated sensitivity in earlier phase II studies [5, 6].
Similarly, low rates of 12-week progression-free survival in patients with
adipocytic sarcomas treated in a phase II trial of pazopanib informed the exclu-
sion of this subtype from the subsequent phase III trial that met its primary PFS
outcome and led to the approval of pazopanib [11••, 51]. Whilst the timely
recruitment of phase III cohorts consisting of a single or few STS subtypes has
been considered impractical, recent studies have challenged this axiom by calling
upon increasingly robust national and international collaborations [12••, 29].
The recently reported phase III trial of neoadjuvant chemotherapy performed by
the Italian SarcomaGroup demonstrates the feasibility of completion of subtype-
adaptive randomised protocols [52]. Accordingly, the focusing of phase III
investigation of new drugs in pre-selected subtypes represents a viable and
rational approach.
Rapid progressors
In all recently reported STS phase III studies, between 25 and 50% of patients in
both control and investigative arms experienced a progression event by the time
of first protocol-mandated radiological assessment. With PFS curves
superimposed to this point, in all summarised studies there is then a divergence
of survival rates between control and investigative arms. In the cases of eribulin
and trabectedin, the magnitude of effect of investigative agent was demonstrably
sufficient to indicate a significant OS or PFS advantage. However, in PICASSO III
and SARC021, the effect size of palifosfamide and evofosfamide was insufficient
to demonstrate of significant difference after late separation of PFS curves.
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Why do up to half of patients enrolled in advanced STS trials experience early
progression, and can they be prospectively identified? The factors that contribute
to early progression are likely numerous and variable. One possibility is that
variation in assessment of performance status and life expectancy within large
international, multi-centre studies results in the enrolment of patients already
experiencing an irreversible terminal decline. Such a phenomenon is not how-
ever indicated by trial subgroup data, where little difference in treatment effect is
reported between patients of PS 0 compared to those with PS 1 or 2. Similarly,
any association between histopathological features and early progression would
be expected to be revealed in subgroup analysis. It is plausible that currently
uncharacterised aspects of disease biology are shared between rapidly progressing
cases which, if identified, could be used to stratify trial populations as well as
uncovering important disease drivers to serve as novel drug targets.
High rates of early progression remove significant proportions of trial cohorts
from the at-risk population, thus diminishing the trial’s power to demonstrate
any significant difference in outcome between patients who continue with
protocol therapy beyond first radiological assessment. More research is required
to understandwhy somany STS trial patients experience early progression and to
developmeans of prospectively identifying such patients in order to stratify study
design and/or redirect poor prognosis patients away from futile therapies and
toward supportive care measures.
Where do we now go?
The full FDA approval of two new drugs in the past year represents an unprec-
edented rate of advance in the advanced STS armamentarium. However, the
attrition rate of phase III trial to drug approval remains high and represents a
disappointing output from significant investment of resources. Recent trial
outcomes provide instruction for the design of future studies, all of which will
rely upon ongoing national and international collaboration.
‘All-comer’ recruitment has been a common element of several recent neg-
ative STS phase III studies. A model of subtype preselection through use of
surrogate progression-free and response endpoints in smaller phase II trials has
proven to be more fruitful and should be followed in future drug development
to reduce the biological heterogeneity within phase III cohorts. The develop-
ment of tumour-based predictive and prognostic biomarkers should be at the
forefront of all translational phase II and III endpoints to provide the means of
cohort stratification and focusing of drug effect on sensitive biology. Reported
tools ofmolecular stratification, such as the 67 gene CINSARC signature or gene
expression-defined LMS subtypes, should be included in pre-specified sub-
group analyses of trials in relevant STS subtypes [53, 54•].
Recent trial evidence suggests a new benchmark for estimated survival in
doxorubicin control arms of first-line advanced STS trials. With the availability
of up to six standard lines of systemic therapy for many STS subtypes, the use of
OS as a primary endpoint in first-line advanced STS trials may now be unfea-
sible. Instead, wider use of PFS as a primary endpoint in this setting should be
accompanied by greater effort to demonstrate definitive validity as a surrogate
for OS, as well as the development of more sensitive and specific means for
radiological assessment of response. The development of new imaging
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modalities that include dual energy CT, diffusion-weighted MRI and PET
should be incorporated into the phase II and III development of new drugs in
STS as ameans ofmore accurate identification of sensitive subtypes. OS remains
a viable secondary endpoint in trials in the pre-treated setting, but meticulous
collection and reporting of post-trial treatments will be essential to establish the
sources of any confounding or bias.
Finally, the broad availability of single patient-level baseline histo-
logical and clinical characteristics as well as efficacy data is essential for
the detailed interpretation of STS phase III results. There is clear evi-
dence across numerous drug trials that there are currently undefined
patient subgroups that experience differential treatment responses and
disease phenotypes.
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